Lesotho mothers welcome the reintroduction of HPV vaccine
- Impact
- Lesotho mothers welcome the reintroduction of HPV vaccine
Lesotho mothers welcome the reintroduction of HPV vaccine
31 May 2022
Pupils at the Masianokeng High School. Credit: Monyane Khau.
Seven years after it ended, Lesotho has relaunched its HPV vaccination programme.
Seven years after it ended, Lesotho has relaunched its HPV vaccination programme.
By Monyane Khau
Announcements
IFFIm impact: HPV
Vaccine bonds enabled IFFIm to disburse US$ 66 million to Gavi for HPV immunisation programmes helping protect 3.9 million girls from the leading cause of cervical cancer.
’Manthati Tšeloa, a Food and Nutrition teacher at Masianokeng High School in Maseru, lost her friend to cervical cancer six years ago.
“The most important thing is to prevent rather than treat cervical cancer,” she says. “Right now, the rates at which women in Lesotho are diagnosed with cervical cancer is shocking. Honestly, my biggest wish is that my students do not add to the statistics.”
According to the Elizabeth Glaser Paediatric Aids Foundation, cervical cancer incidence in Lesotho is among the highest in the world, and it is the most common type of cancer in Basotho women. The cancer killed 346 of the 514 Basotho women diagnosed with the disease in 2020.
Health Minister Semano Sekatle says the cost of treating cancer patients is high, with the government spending “over M100,000 on the treatment of one cervical cancer patient”.
Fortunately, in early May, girls at Tseloa’s school who are between the ages of nine and 14 years received their human papillomavirus (HPV) vaccine shots.
Ntaote wants to be a doctor when she grows up and was ecstatic when her mother permitted her to get vaccinated as this would limit her chances of dying before her dream comes true.
This came after the Lesotho government reintroduced the HPV vaccination programme in April to help prevent cervical cancer. The initial programme, whose coverage was 91%, was abandoned in 2015 due to financial constraints.
Ministry of Health official Susan Ramakhunoane says the WHO advises that the HPV vaccine is mostly effective when taken before one’s 16th birthday.
“HPV is sexually transmitted, and, while sexual activity is very low within that age group, it is important that the vaccine be administered to women of any age group. The challenge in Lesotho is a lack of resources and so we are concentrating on girls because they are most vulnerable,” Ramakhunoane adds.
Tšeloa has welcomed the move saying, “These girls are very fortunate. We have been encouraging parents to allow their children to get vaccinated because, in some cases, parents prevent their children from receiving vaccines.”
Felleng Mahlehle (15), Karabo Ntaote (13) and Retsepile Ntjana (14) received their shots on 4 May 2022.
Mahlehle says, “I turned 15 years old a few days after being vaccinated. I feel blessed. My mother was over the moon when she heard about the programme.”
She adds, “The principal, ‘Mapesha Lehohla, told us about how cervical cancer is killing many women in the country. I am not sexually active, but I don’t think receiving the vaccine means I must have multiple sexual partners.”
Ntaote wants to be a doctor when she grows up and was ecstatic when her mother permitted her to get vaccinated as this would limit her chances of dying before her dream comes true.
“Cervical cancer is caused by a sexually transmitted virus. While I strongly believe that girls must not be sexually active until they are at least 20 years, it was important for me to get vaccinated because I want to live a fulfilled life of curing people,” Ntaote says.
For Ntjana, her decision was influenced by her older sister sharing stories of New Millennium International School students who vaccinated earlier than Masianokeng High School learners.
“My sister didn’t not receive the vaccine because she is over 14 years old but she kept telling me and my mother about this HPV vaccine students at her school received. She was envious of them,” Ntjana says.
In a Basotho mothers only group on Facebook, comments from mothers were all positive.
Lineo Motsamai says, “The reintroduction was ‘a dream come true’ (because of) the rate at which cervical cancer is attacking us.”
'Mamots'eare Sebolai adds, “My first born took it but her younger sister and my niece missed the opportunity to receive their shots because there was no vaccine at the time they qualified.”
Another parent, 'Maitumeleng Rankhone says: “I honestly support the initiative if you can see the shocking numbers of cancer patients at Senkatana (Centre of Excellence). I was definitely going to receive my shot if I qualified.”
Lindiwe Moyo says, “I am glad my daughter did it almost a decade ago. Of all types of cancers that she may have, at least I know that she is protected from this one (cervical cancer). I constantly go for cancer screening at Senkatana after every two years. It is painful to see the line with Basotho women.”
Senkatana Centre of Excellence runs, among others, a cervical cancer prevention programme in Maseru.
'Masekhants'o Moiloa says she was scared her daughter would not have her shot as years progressed without HPV programme in place, adding “I was over the moon when they reintroduced this programme”.
This article is republished from VaccinesWork under a Creative Commons license. Read the original article. |
Since the start of Gavi’s human papillomavirus (HPV) vaccine programme in 2012, 3.9 million girls have been protected against the leading cause of cervical cancer, and demand for HPV vaccine has never been higher. Thanks to vaccine bonds that raise immediate money on capital markets backed by donor pledges, IFFIm has disbursed US$ 66 million to Gavi for HPV since 2006. Today, the lowest-income countries now have access to HPV vaccines for as little as US$ 4.50 per dose. The same vaccines can cost more than US$ 100 in high-income countries.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024